Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Annovis Bio Inc.

In a report released today, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Annovis Bio, with a price target of $17.00. According...

Market Cap	$45.21M	P/E Ratio	N/A
52W High	$7.52	52W Low	$1.11
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	41.8%
Overall Score	71	Value Score	60
Quality Score	--	Technical Score	83

EPS Current Est	$-1.41	EPS Next Est	$-1.51
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ANVS	$3.79	-2.32%	1.97M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ANVS	$3.79	-2.3%	1.97M
3
4
5
6

ANVS

ANVS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Annovis Bio Inc. Data in Excel

Get Annovis Bio Inc. Data in Excel